Skip to main content

Day: March 4, 2026

Castellum, Inc. Announces 2025 Unaudited Financial Results

Castellum, Inc. Announces 2025 Unaudited Financial ResultsCastellum, Inc. (NYSE-American: CTM), announces certain unaudited highlights of its operating results for its year ended December 31, 2025 – www.castellumus.comVIENNA, Va., March 04, 2026 (GLOBE NEWSWIRE) — Castellum, Inc. (“Castellum” “CTM”, “we” or the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, announces certain unaudited highlights of its operating results for its year ended December 31, 2025. Revenue for 2025 increased to $52.9 million, representing an $8.1 million (15.2%) increase over $44.8 million in 2024. Operating loss improved to $2.8 million, a $4.4 million year-over-year improvement from an operating loss of $7.2 million in 2024. Net loss to common shareholders...

Continue reading

NN, Inc. Reports Fourth Quarter and Full Year 2025 Results

NN delivers third consecutive year of successful transformation; completes majority of heavy spending NN forecasts fourth year of improvement, and a return to organic net sales growth in 2026 CHARLOTTE, N.C., March 04, 2026 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR) (“NN” or the “Company”), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, today reported its financial results for the fourth quarter and full-year ended December 31, 2025. Key results include: Financial HighlightsQ4 2025 net sales of $104.7 million and full-year 2025 net sales $422.2 million Q4 2025 gross margin of 9.2% and full-year 2025 gross margin of 14.1% Q4 2025 adjusted gross margin of approximately 18.8%, up 120 bps and approaching the Company’s five-year target of 20% Q4 2025 operating...

Continue reading

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent HighlightsDelivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basis Achieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period last year and a decrease of 7% on a constant currency basis Realized gross margin of 78% in the fourth quarter of 2025 and 74% for the full year of 2025 Refinanced existing debt, securing up to $60 million in committed capital under a new 5-year interest-only...

Continue reading

Rigetti Computing Reports Fourth Quarter and Full-Year 2025 Financial Results

Demonstrates 99.9% two-qubit gate fidelity at 28 nanosecond gate speed on prototype platform BERKELEY, Calif., March 04, 2026 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full-Year 2025 Financial HighlightsTotal revenues for the three months ended December 31, 2025 were $1.9 million Operating loss for the three months ended December 31, 2025 was $22.6 million For the three months ended December 31, 2025: GAAP net loss $18.2 million; non-GAAP net loss $11.3 million For the three months ended December 31, 2025: GAAP net loss per share $(0.06); non-GAAP net loss per share $(0.03) For the year ended December 31, 2025: Total...

Continue reading

red violet Announces Fourth Quarter and Full Year 2025 Financial Results

Fourth Quarter Revenue Increased 20% to a Record $23.4 Million Full Year 2025 Revenue Increased 20% to $90.3 Million, Generating GAAP EPS of $0.91 BOCA RATON, Fla., March 04, 2026 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the fourth quarter and full year ended December 31, 2025. “We concluded 2025 with record fourth quarter results, capping a year defined by disciplined execution and continued momentum across the enterprise,” stated Derek Dubner, red violet’s CEO. “Our cloud-native architecture, embedded artificial intelligence, and extensive longitudinal identity graph continue to differentiate us in the marketplace, particularly in regulated and mission-critical environments. The durability and scalability of our model are...

Continue reading

Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026.   Recent Financial HighlightsGenerated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2024. Achieved total gross margin of 87% in the fourth quarter of 2025 compared to 87% in the same period in the prior year,...

Continue reading

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited financial results for the year ended December 31, 2025. Management’s Discussion: “Today we are reporting 2025 net operating income of $1.6 million, an increase of $3.3 million compared to 2024. These results were largely driven by a significant improvement in gross margin, reflecting higher volumes, manufacturing efficiencies, and price realization,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “Net loss for 2025 was $1.0 million, an improvement of $1.1 million compared to 2024. As previously discussed, we saw several non-recurring items in 2025...

Continue reading

Alto Ingredients, Inc. Reports Fourth Quarter and Year-end 2025 Results

– Results Improved in All Segments – – Q4 2025 Gross Profit of $15.2 Million Increased $16.6 Million, Q4 2025 Net Income of $21.5 Million, or $0.28 per Share, Improved $63.5 Million, and Q4 2025 Adjusted EBITDA of $27.9 Million Grew $35.6 Million Compared to Q4 2024 – PEKIN, Ill., March 04, 2026 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, reported its financial results for the quarter and year ended December 31, 2025. President and Chief Executive Officer Bryon McGregor commented, “The fourth quarter capped a year of strong execution and marked a pivotal milestone in our strategic realignment. Over the course of 2025, we completed the heavy lifting of addressing losses at underperforming assets,...

Continue reading

BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) — BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026. Financial Highlights:Total revenue of $96.1 million in the fourth quarter of 2025, compared to $45.1 million in the fourth quarter of 2024, an increase of 113%. Prenatal clinical testing revenue was $86.1 million in the fourth quarter of 2025, an increase of 99% from the fourth quarter 2024. Oncology clinical testing revenue was $9.1 million in the fourth quarter of 2025, more than 8x higher than the $1.1 million reported in the fourth quarter of 2024. Gross profit margin was...

Continue reading

Hudson Technologies Reports Fourth Quarter and Year-End 2025 Results

28% growth in fourth quarter revenue to $44.4 million Annual refrigerant sales volume grew by 6% Annual refrigerant reclamation volume increased by 18% for second consecutive year Maintained strong, unlevered balance sheet Completed accretive acquisition of Refrigerants Inc. Board approved $20 million share repurchase authorization for 2026WOODCLIFF LAKE, N.J., March 04, 2026 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) announced results for the fourth quarter and year ended December 31, 2025. Kenneth Gaglione, President and Chief Executive Officer of Hudson Technologies commented, “Hudson delivered a strong finish to 2025 with fourth quarter results that included revenue growth of 28% and the successful execution of our accretive acquisition of Refrigerants Inc. “We also achieved a second consecutive year of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.